Veenat 100mg Capsule

Veenat 100mg Capsule belongs to a class of medication known as tyrosine kinase inhibitors as it contains Imatinib as an active ingredient. It is an anticancer medicine that is commonly prescribed to treat certain blood cancers like chronic myeloid leukemia & acute lymphocytic leukemia, and gastrointestinal stromal tumors. It works as a specific inhibitor of several tyrosine kinase enzymes. After the oral administration, the effect of this medicine can be observed in 2-4 hours.

• Blood cancer (Chronic myeloid leukaemia & acute lymphocytic leukemia)
• Gastrointestinal stromal tumor

Like any other medicine, Veenat 100mg Capsule also has some adverse effects on the body, and most of them are manageable without special medical attention.
Some common side effects include:

• Muscle cramp
• Musculoskeletal (bone, muscle or joint) pain
• Rash
• Weight gain
• Edema (swelling)
• Nausea
• Vomiting
• Diarrhea
• Fatigue
• Abdominal pain
• Bleeding
• Breathing problems
• Cough
• Dizziness
• Dry eye
• Hemorrhage

Do not forget to discuss the risks and benefits of this medication with your doctor. Seek medical attention immediately in case of any severe issues.

• Take Veenat 100mg Capsule as prescribed by your doctor. Swallow it as a whole with water and don't chew, crush, or break it.
• This tablet should be taken with or after food. Take it at the same time every day for effective results. Don't miss a dose or overdose the medicine.
  
  

Veenat 100mg Capsule is an anti-cancer medication. It works by acting on a protein enzyme known as bcr-abl tyrosine kinase that is responsible for the uncontrolled growth of cancerous cells. By inhibiting the action of this enzyme it effectively controls the growth and multiplication of cancer cells and slows down the progression of cancer.

• ​Moen, M. D., McKeage, K., Plosker, G. L., & Siddiqui, M. A. A. (2007). Imatinib: a review of its use in chronic myeloid leukaemia. Drugs, 67(2), 299-320. https://pubmed.ncbi.nlm.nih.gov/17284091/
• Sacha, T. (2014). Imatinib in chronic myeloid leukemia: an overview. Mediterranean journal of hematology and infectious diseases, 6(1), e2014007. https://pubmed.ncbi.nlm.nih.gov/24455116/
• Manley, P. W., Cowan-Jacob, S. W., Buchdunger, E., Fabbro, D., Fendrich, G., Furet, P. ... & Zimmermann, J. (2002). Imatinib: a selective tyrosine kinase inhibitor. European journal of cancer, 38, S19-S27. https://pubmed.ncbi.nlm.nih.gov/12528769/
• Iqbal, N., & Iqbal, N. (2014). Imatinib: a breakthrough of targeted therapy in cancer. Chemotherapy research and practice, 2014(1), 357027. https://pubmed.ncbi.nlm.nih.gov/24963404/
• Deininger, M., Buchdunger, E., & Druker, B. J. (2005). The development of imatinib as a therapeutic agent for chronic myeloid leukemia. Blood, 105(7), 2640-2653. https://pubmed.ncbi.nlm.nih.gov/15618470/
• Peng, B., Lloyd, P., & Schran, H. (2005). Clinical pharmacokinetics of imatinib. Clinical pharmacokinetics, 44(9), 879-894. https://pubmed.ncbi.nlm.nih.gov/16122278/